Aelis Farma Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
28
- Stock Symbol
-
AELIS
- Share Price
-
$1.30
- (As of Friday Closing)
Aelis Farma General Information
Description
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.
Contact Information
Website
www.aelisfarma.comCorporate Office
- 1 rue Lafaurie de Monbadon
- 146, rue Léo Saignat
- 33000 Bordeaux
- France
Corporate Office
- 1 rue Lafaurie de Monbadon
- 146, rue Léo Saignat
- 33000 Bordeaux
- France
Aelis Farma Stock Performance
As of 20-Jun-2025, Aelis Farma’s stock price is $1.30. Its current market cap is $17.7M with 13.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.30 | $1.30 | $1.10 - $13.84 | $17.7M | 13.6M | 30.4K | -$0.60 |
Aelis Farma Financials Summary
As of 31-Dec-2024, Aelis Farma has a trailing 12-month revenue of $2.9M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 20,302 | 20,302 | 167,355 | 143,301 |
| Revenue | 2,898 | 2,898 | 9,797 | 4,005 |
| EBITDA | (7,766) | (7,766) | (5,409) | (14,811) |
| Net Income | (8,068) | (8,068) | (5,495) | (15,022) |
| Total Assets | 20,506 | 20,506 | 29,051 | 42,057 |
| Total Debt | 6,332 | 6,332 | 4,467 | 4,101 |
Aelis Farma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aelis Farma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Aelis Farma Comparisons
Industry
Financing
Details
Aelis Farma Competitors (2)
One of Aelis Farma’s 2 competitors is Zynerba Pharmaceuticals, a Formerly VC-backed company based in Plymouth, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zynerba Pharmaceuticals | Formerly VC-backed | Plymouth, PA | ||||
| Ambrx | Formerly PE-Backed | San Diego, CA |
Aelis Farma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aelis Farma Patents
Aelis Farma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3669876-A1 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | Inactive | 18-Dec-2018 | ||
| EP-3897655-A1 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | Active | 18-Dec-2018 | ||
| JP-2022515373-A | 3β- (benzyloxy) -17α-methyl-pregun-5-en-20-on for use in the treatment of cognitive impairment | Active | 18-Dec-2018 | ||
| AU-2019409912-A1 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | Active | 18-Dec-2018 | ||
| AU-2019409912-A8 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | Active | 18-Dec-2018 | C07J7/009 |
Aelis Farma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aelis Farma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aelis Farma ESG
Risk Overview
Risk Rating
Updated December, 01, 2023
26.97 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,048
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Aelis Farma FAQs
-
When was Aelis Farma founded?
Aelis Farma was founded in 2013.
-
Where is Aelis Farma headquartered?
Aelis Farma is headquartered in Bordeaux, France.
-
What is the size of Aelis Farma?
Aelis Farma has 28 total employees.
-
What industry is Aelis Farma in?
Aelis Farma’s primary industry is Drug Discovery.
-
Is Aelis Farma a private or public company?
Aelis Farma is a Public company.
-
What is Aelis Farma’s stock symbol?
The ticker symbol for Aelis Farma is AELIS.
-
What is the current stock price of Aelis Farma?
As of 20-Jun-2025 the stock price of Aelis Farma is $1.30.
-
What is the current market cap of Aelis Farma?
The current market capitalization of Aelis Farma is $17.7M.
-
What is Aelis Farma’s current revenue?
The trailing twelve month revenue for Aelis Farma is $2.9M.
-
Who are Aelis Farma’s competitors?
Zynerba Pharmaceuticals and Ambrx are competitors of Aelis Farma.
-
What is Aelis Farma’s annual earnings per share (EPS)?
Aelis Farma’s EPS for 12 months was -$0.60.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
